Are natural killer cells superior CAR drivers?
Hans KlingemannTufts University School of Medicine; Boston, MA USA ; Conkwest Inc.; Cambridge, MA USA
2014en
ABI
Abstract
T lymphocytes engineered to express a chimeric antigen receptor (CAR) are being celebrated as a major breakthrough of anticancer immunotherapy. Natural killer cells have not received similar attention as CAR effectors, although the use of these relatively short-lived cytotoxic cells is associated with several advantages.
Identifiers
Citations and references
Cited by 20 references